Krsnaa Diagnostics Presents Investor Presentation for Q1 FY27 Results
Krsnaa Diagnostics reported Q1 FY27 consolidated revenue of ₹2,355 million, up 22% YoY. Retail revenue surged 64% YoY to ₹118 million. PAT declined 19% to ₹166 million. The company is expanding its network and focusing on retail-led growth strategies.
The mixed financial results, with revenue growth but declining profitability, and the strategic focus on future growth initiatives, suggest a medium impact on investor sentiment.
While revenue and retail business showed strong growth, the decline in PAT and margins indicates mixed performance, leading to a neutral sentiment.
Krsnaa Diagnostics Limited has released an investor presentation detailing its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a consolidated revenue of ₹2,355 million for Q1 FY27, a 22% increase from ₹1,930 million in Q1 FY26. EBITDA saw a 12% rise to ₹588 million from ₹524 million, though the EBITDA margin contracted by 221 basis points to 25% from 27%. Profit After Tax (PAT) decreased by 19% to ₹166 million from ₹205 million, with the PAT margin declining to 7% from 11%.
The company highlighted significant growth in its retail business, with retail revenue increasing by 64% year-on-year to ₹118 million in Q1 FY27. Patient count in the retail segment grew by 75% YoY to 0.21 million, and test volumes rose by 47% YoY to 0.47 million. Retail revenue's contribution to group revenue increased to 8% from 1% in the previous year.
Krsnaa Diagnostics emphasized its expanding network, with over 200 CT/MRI centers and 212 pathology labs. The company is focused on scaling its retail operations through geographic expansion, deepening network depth, promoting preventive wellness, increasing retail radiology penetration, scaling home collection services, and enhancing digital conversion across all business channels. The presentation also underscored the company's competitive advantages, including its extensive reach, capacity, and focus on affordability, aiming for 'Cash Growth' in the next phase.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.